Petvivo Holdings . Common Stock Stock Earnings Reports

PetVivo reported strong Q1 FY2026 operational momentum with total revenue of $298,000, a 141% year-over-year increase, driven largely by distributor sales that rose 192% to $198,000 and represented 67% of revenue. Gross profit was $187,000 (63% margin) though margin compression was attributed to the addition of the PrecisePRP product line. Operating expenses fell 9% to $2.0 million, helping reduce operating loss by 10% to $1.8 million. Net loss available to common stockholders was $2.3 million, or $0.09 per share, an improvement versus the prior year. Cash on hand increased materially to $3.3 million from $220,000 at March 31, 2025, largely due to $4.7 million of financing activity during the quarter. Total liabilities declined about 39% quarter-over-quarter. The company achieved an uplisting to the OTCQX market. Key commercial and strategic developments include U.S. commercialization rights for PrecisePRP (an off-the-shelf allogeneic PRP product), expanded distributor footprint including the first distributor in Mexico, ongoing clinical studies (including a canine elbow pilot), and several partnerships: VetStem (PrecisePRP), Digital Landia (pet AI integration with expected commercial launch in Q3), Commonwealth Markets (equine adoption), and PiezoBioMembrane (R&D on biodegradable piezoelectric biomaterials). Management expects continued strong sales momentum and market penetration through FY2026, citing favorable industry tailwinds and multiple product and technology integrations to drive adoption.